KRAS and non-small cell lung carcinoma: One of the most frequent oncogenic drivers in advanced non-small cell lung cancer is mutant KRAS, and typically, it is expressed in a mutually exclusive manner; that is, it is not expressed with other clinically relevant driver mutants, like EGFR, BRAF or ALK mutation, although it is frequently comutated with the tumor suppressor genes STK11, TP53, and CDKN2A/CDKN2B(Davis et al., 2021; Veluswamy et al., 2021; Punekar et al., 2022).